Review

Organ-organ communication: The liver’s perspective

Fei Wang1, Kwok-Fai So2,3, Jia Xiao4 and Hua Wang5,6

1. Division of Gastroenterology, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
2. GMH Institute of CNS Regeneration, Guangdong Medical Key Laboratory of Brain Function and Diseases, Jinan University, Guangzhou, China.
3. Laboratory of Neuroendocrinology, Fujian Key Laboratory of Developmental and Neurobiology, School of Life Sciences, Fujian Normal University, Fuzhou, China.
4. Clinical Medicine Research Institute and Department of Interventional Surgery, First Affiliated Hospital of Jinan University, Guangzhou, China.
5. Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.
6. Inflammation and Immune Mediated Disease Laboratory of Anhui Province; School of Pharmacy, Anhui Medical University, Hefei, China.

Corresponding authors: Hua Wang, MD, PhD. E-mail: wanghua@ahmu.edu.cn; or Jia Xiao, PhD. E-mail: edwinsiu@connect.hku.hk

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.11.12; Accepted: 2020.12.28; Published: 2021.01.16

Abstract

Communication between organs participates in most physiological and pathological events. Owing to the importance of precise coordination among the liver and virtually all organs in the body for the maintenance of homeostasis, many hepatic disorders originate from impaired organ-organ communication, resulting in concomitant pathological phenotypes of distant organs. Hepatokines are proteins that are predominantly secreted from the liver, and many hepatokines and several signaling proteins have been linked to diseases of other organs, such as the heart, muscle, bone, and eyes. Although liver-centered interorgan communication has been proposed in both basic and clinical studies, to date, the regulatory mechanisms of hepatokine production, secretion, and reciprocation with signaling factors from other organs are obscure. Whether other hormones and cytokines are involved in such communication also warrants investigation. Herein, we summarize the current knowledge of organ-organ communication phenotypes in a variety of diseases and the possible involvement of hepatokines and/or other important signaling factors. This provides novel insight into the underlying roles and mechanisms of liver-originated signal transduction and, more importantly, the understanding of disease in an integrative view.

Key words: Liver; Organ communication; Hepatokine; Cytokine; Disease mechanism.

Introduction

Over the past 30 years, we have witnessed advances in the understanding of how organs and tissues communicate under healthy and pathologic conditions by secreting proteins, lipids, metabolites, and small noncoding RNAs. Now, it is considered that most tissues are able to communicate with local and distant tissues/organs in an autocrine/paracrine/endocrine manner. Interorgan and intertissue communication is increasingly recognized as a critical way to maintain homeostasis and disease adaptation [1]. Furthermore, molecular biology has provided a toolkit to identify the functions of circulating proteins, such as hormones and cytokines, as communication messengers. Indeed, many new communication proteins are yet to be discovered that will widen our knowledge of organ-organ communication loops and provide potential novel strategies for treating some degenerative diseases [2].

The liver performs a number of essential functions related to detoxification, nutrient storage, digestion, metabolism, and immunity. Liver diseases, including viral hepatitis, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), autoimmune hepatitis (AIH), fibrosis, and end-stage liver disease, account for approximately 2 million deaths per year worldwide [3]. Clinically, both acute and chronic liver diseases have evident extrahepatic complications, which in turn determine the disease progression and efficacy of therapy, forming ‘organ-organ communication’ [4, 5]. Thus, understanding the interorgan communicating mechanisms, especially the molecular mediators...
therein is important for the development of targeted therapies.

**Communicating molecules derived from the liver**

Although first identified in metabolic diseases (e.g., NAFLD and type 2 diabetes), signaling proteins exclusively or predominantly secreted from the liver termed ‘hepatokines’ are now known to directly affect other diseases. Hepatocytes secrete more than 560 types of hepatokines, many of which regulate metabolic and inflammatory diseases in the liver or at distant organs (e.g., the endocrine roles of hepatokines in bone and heart tissues) through circulation delivery [6]. Under extreme challenges, such as long-term starvation or overnutrition, the liver may secrete hepatokines to influence energy homeostasis and inflammation. Indeed, if the liver is unable to fulfill this process, the corresponding disease develops, such as steatosis from impaired hepatic insulin-sensitizing substance production [7].

**Fibroblast growth factor-21**

Fibroblast growth factor-21 (FGF-21) is a hormone predominantly secreted by the liver to regulate glucose metabolism in adipocytes in addition to insulin activity. It has been recognized as a therapeutic target of obesity and diabetes [8]. Injection of recombinant FGF-21 in obese mice successfully ameliorated hepatic steatosis, glucose intolerance, and insulin resistance through increased insulin production and secretion [9]. Recent studies also identified FGF-21 as a biomarker for a variety of human diseases, including metabolic disorders [10], drug-induced liver injury [11], hypertension [12], and mitochondrial disease [13]. Currently, the findings of high FGF-21 levels in those patients conflict with the beneficial effects of exogenous FGF-21 administration in patients with obesity and those with diabetes, which might be attributed to possible FGF-21 resistance, suggesting that high levels of FGF-21 are a compensation mechanism in response to metabolic stress in those patients.

**Adropin**

Adropin is a recently identified small peptide for the maintenance of energy homeostasis and insulin resistance. Its plasma level is positively correlated with nutritional status, that is, upregulated upon feeding and downregulated with fasting [14]. Patients with NAFLD, obesity, and cardiovascular disease are reported to have low levels of adropin, indicating that this peptide is associated with metabolic disorders [15]. In a NAFLD mouse model, overexpression of adropin significantly improved insulin resistance and glucose intolerance [16]. Moreover, muscle insulin signaling was also improved through the amelioration of mitochondrial dysfunction [17]. When adropin was knocked out, mice exhibited increased adiposity, dyslipidemia and whole-body insulin resistance [18]. A recent study unveiled the regulatory effects of adropin on fuel substrate utilization in the heart, probably via a novel G protein coupled receptor (GPCR)-mitogen-activated protein kinase (MAPK)-signaling pathway [19]. Adropin protein expression falls progressively with advancing age in the human peripheral vasculature. Restoration of adropin may facilitate the improvement in endothelial function via increased nitric oxide bioavailability [20].

**Angiotensinogen**

The renin-angiotensin system (RAS) is pivotal to the regulation of blood pressure and water/sodium metabolism. As a hepatokine, angiotensinogen (AGT) is the only precursor of all angiotensin peptides. Accumulating evidence shows that AGT is not only a passive substrate of the RAS, but also plays a critical role in the pathogenesis of obesity and atherosclerosis. Transgenic human AGT in mice showed augmented atherosclerosis when fed a high-fat diet for 14 weeks [21]. Hepatocyte-specific knockout of AGT in mice resulted in lowered body weight and ameliorated liver steatosis/atherosclerosis after high-fat diet feeding [22]. Indeed, deficiency of AGT could reduce basal plasma AGT levels and blood pressure and induce renal medial hyperplasia [23]. Since adipose tissue is the only extrahepatic source to have an impact on plasma AGT concentration, the sole role of adipocyte-derived AGT and the communication between the liver and adipose tissue during disease progression have attracted mass attention in recent years. Adipocyte-specific deficiency of AGT decreased systolic blood pressure and prevented obesity-induced hypertension in mice [24, 25].

**Fetuins**

Both fetuins-A and-B are important hepatokines in human metabolism regulation. Fetuin-A was first identified as a natural inhibitor of the insulin receptor tyrosine kinase in liver and skeletal muscle. Deficiency of fetuin-A in mice exhibited improved phenotypes of insulin signaling [26]. Human studies also confirmed that, independent of adiposity, circulating fetuin-A levels positively correlated with high liver fat content, early atherosclerosis, and metabolic syndrome [27, 28]. In addition, fetuin-A induces insulin resistance and inflammation via multiple mechanisms, including the activation of the extracellular signal regulated-kinase-nuclear factor kappaB (ERK-NF-κB) pathway [29], promoting
saturated fatty acid-induced activation of toll-like receptor 4 [30], inducing proinflammatory cytokine production in monocytes and adipocytes [31], and inhibiting insulin-sensitizing adiponectin production [32]. Recent articles also described the critical roles of fetuin-A in diseases of other organs, such as the heart, kidneys, and bone, which will be discussed in the following sections. Like fetuin-A, fetuin-B is also a liver-derived plasma protein. It is increased in patients with type 2 diabetes and impairs insulin sensitivity in myotubes and hepatocytes [33]. The current knowledge of the effects of liver-secreted cytokines and hepatokines on distant organs under physiological and pathological conditions is illustrated in Figure 1 and Table 1.

Communications between the liver and other major organs

Gut-liver-brain axis

The concept of the gut-liver-brain axis was first reported in the study of lipid metabolism and glucose synthesis by Wang, et al. in 2008 [34]. To date, this axis is the most well-studied interorgan pathway for the liver. Bile acids (BAs), the metabolites of cholesterol, have long been considered to play an essential role in lipid digestion and fat-soluble vitamin absorption. Two typical bile acid receptors, farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5), are abundantly expressed not only in the enterohepatic circulation but also in the brain [35, 36]. Thus, studies have focused on the central nervous system activities in which BAs are involved [37, 38]. A recent study discussed the relationship among bile acids, intestinal microbiota and Alzheimer’s disease in which the interaction between bile acids and intestinal microbiota influenced the function of the brain [39]. Mechanistically, intestine-restricted agonism of FXR induced TGF5 activity, promoted secretion of FGF-15/21 to improve insulin resistance and promote white adipose tissue browning in mice [40]. This provides a theoretical basis for the direct or indirect risk factors of cognitive decline diseases caused by cholesterol metabolism disorder, including cholestatic liver disease, dyslipidemia, fatty liver disease, cardiovascular disease and diabetes.

Hepatic encephalopathy (HE) manifests as brain dysfunction caused by liver diseases, and portosystemic shunting is one of the late complications of cirrhosis [41]. HE occurs due to different pathogeneses in which hyperammonemia and gut-derived toxins (e.g. indoles, oxindoles and endotoxins) have been considered to be the major pathological causes. Ammonia and the proinflammatory environment are mainly derived from intestinal microbiota, especially Enterobacteriaceae and Streptococcaceae, and subsequently, ammonia is transported to the liver and metabolized [42, 43]. The critical involvement of Kupffer cells in HE pathogenesis was revealed in an ammonium acetate-challenged model where specific deletion of TLR9 in macrophages ameliorated brain edema and lymphocyte cytokine production [44]. Since the ammonia levels in chronic liver failure do not reliably correlate with HE severity and many HE cases are caused in an ammonia-independent manner, treating HE through microbiota modulation (e.g. lactulose and rifaximin) has up to now been considered a first line of intervention [45].
IGF-1 (insulin-like growth factor 1), leading to which involves an increased secretion of FGF-21 and preference by the liver [51]. Physical exercise is control of simple sugar intake and sweet taste [52].

Improved cognitive function and brain metabolism [53] because only ~15-20% alcohol use disorder patients develop ALD [49]. Physiologically, a complex consisting of one of the FGF-21 receptors (FGFR1c, FGFR2c or FGFR3c) and a single-pass transmembrane protein, β-Klotho, renders FGF-21 signals able to FGFR2c or FGFR3c) and a single-pass transmembrane consisting of one of the FGF-21 receptors (FGFR1c, FGFR2c or FGFR3c) and a single-pass transmembrane protein, β-Klotho, renders FGF-21 signals able to activate the intestinal vagus nerve and transduce the signal to the brain, which then regulates the synthesis of glycogen through the gut-liver-brain axis [34]. Additionally, it was reported that cholecystokinin, protein kinase A, and protein kinase C activation were all involved in regulating the synthesis of glycogen [34].

Adropin improves insulin sensitivity and energy metabolism; Redox control; Cerebellum development [14-17].

Angiotensinogen mostly liver, also adipose tissue, brain, gall bladder, heart, and kidneys Blood pressure and water/sodium metabolism regulations [22-25].

ANGPTLs ANGPTL3, 4, 6, 8; Mostly liver, also adipose tissue and muscle, ANGPTL2 and 5; Mostly heart, also adipose tissue; ANGPTL 7: eyes Lipid and energy regulation; Angiogenesis; Inflammatory regulation; Carcinogenesis and inhibition [61, 62, 67].

Fetuin-A Predominantly liver Induces insulin resistance and inflammation Metabolic disease, I/R injury, CVD, PCOS [27-30, 167].

Fetuin-B Mostly liver, also esophagus and pancreas Causes glucose intolerance; Essential for fertilization Metabolic disease, COPD, CVD, renal disease, osteoporosis [33].

IGFBP-1 Mostly liver, also placenta and endometrium Metabolic regulation; Carcinogenesis, Bone loss, cancer, metabolic disease [106].

AMBP Mostly liver, also gall bladder Direct heme binding CVD, renal disease [115, 132].

Hepcidin Mostly liver, also heart Inhibits iron transport; Regulatory target of interleukin; Strong antimicrobial activity CVD, renal disease [116, 117, 133].

Tsukushi Mostly liver Controls energy expenditure via brown fat sympathometic innervation Metabolic disease [170, 175].

AMBP, alpha-1-microglobulin; ANGPTL, angiopoietin-like protein; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; FGF, fibroblast growth factor; IGFBP-1, insulin-like growth factor binding protein 1; I/R injury, ischemia-reperfusion injury; PCOS, polycystic ovary syndrome.

Table 1. Identified key hepatokines linking hepatic and non-hepatic disorders

| Hepatokine | Organ sources | Key functions | Involved diseases | Refs |
|------------|---------------|---------------|------------------|------|
| FGF-21     | Mostly liver, also thyroid and pancreas | Reverses hepatic steatosis and increases energy expenditure; Immuno-regulation; Blood pressure and hydration controls | Metabolic disease, DILI, cancers, mitochondrial disease | [8, 9] |
| Adropin    | Brain, liver, prostate, testis, stomach | Improves insulin sensitivity and energy metabolism; Redox control; Cerebellum development | Metabolic disease, I/R injury, CVD, PCOS | [14-17] |
| Angiotensinogen | Mostly liver, also adipose tissue, brain, gall bladder, heart, and kidneys | Blood pressure and water/sodium metabolism regulations | Hypertension, atherosclerosis, metabolic disease, renal disease | [22-25] |
| ANGPTLs   | ANGPTL3, 4, 6, 8; Mostly liver, also adipose tissue and muscle, ANGPTL2 and 5; Mostly heart, also adipose tissue; ANGPTL 7: eyes | Lipid and energy regulation; Angiogenesis; Inflammatory regulation; Carcinogenesis and inhibition | Metabolic disease, cardiovascular disease, cancer | [61, 62, 67] |
| Fetuin-A   | Predominantly liver | Induces insulin resistance and inflammation | Metabolic disease, I/R injury, CVD, renal disease, lung disease | [27-30, 167] |
| Fetuin-B   | Mostly liver, also esophagus and pancreas | Causes glucose intolerance; Essential for fertilization | Metabolic disease, COPD, CVD, renal disease, osteoporosis | [33] |
| IGFBP-1    | Mostly liver, also placenta and endometrium | Metabolic regulation; Carcinogenesis | Bone loss, cancer, metabolic disease | [106] |
| AMBP       | Mostly liver, also gall bladder | Direct heme binding | CVD, renal disease | [115, 132] |
| Hepcidin   | Mostly liver, also heart | Inhibits iron transport; Regulatory target of interleukin; Strong antimicrobial activity | CVD, renal disease | [116, 117, 133] |
| Tsukushi   | Mostly liver | Controls energy expenditure via brown fat sympathometic innervation | Metabolic disease | [170, 175] |

The gut-liver-brain axis is also involved in the regulation of glucose metabolism. Intestinal lipids activate the intestinal vagus nerve and transduce the signal to the brain, which then regulates the synthesis of glycogen [34]. In alcoholic liver disease, new evidence shows that coexistent depression and other psychiatric conditions can have a role in ALD progression, because only ~15-20% alcohol use disorder patients develop ALD [49]. Physiologically, a complex consisting of one of the FGF-21 receptors (FGFR1c, FGFR2c or FGFR3c) and a single-pass transmembrane protein, β-Klotho, renders FGF-21 signals able to regulate circadian behavior by acting on the hypothalamus and the dorsal vagal complex of the hindbrain [50]. FGF-21 also mediates endocrine control of simple sugar intake and sweet taste preference by the liver [51]. Physical exercise is known to improve both hepatic and brain health, which involves an increased secretion of FGF-21 and IGF-1 (insulin-like growth factor 1), leading to improved cognitive function and brain metabolism [52].

Liver-adipose tissue communication

Expandability of adipose tissue directly contributes to the progression of metabolic liver diseases, such as NAFLD and ALD [53]. When adipose tissue reaches the upper limit of lipid storage capacity, excessive lipids will be redirected to other organs, most notably the liver. This process warrants a precise modulation of extracellular matrix remodeling and neovascularization of adipocytes. Once deregulated, hypertrophic subcutaneous adipocytes induce lipolysis and to secrete more pro-inflammatory cytokines (e.g. TNF-α and IL-1β), which promote local and hepatic insulin resistance and inflammation [54, 55]. In opposite, a hyperplastic expansion, where the number of adipocytes increases, is thought to be linked to the maintenance of normal insulin sensitivity [56]. We recently reported that chronic-binge ethanol consumption significantly reduced both the mass and adipocyte size of white adipose tissues and increased the secretion of pro-lipolysis and inflammatory molecules (e.g. adipose triglyceride lipase, TNF-α, and IL-6), which aggravated the severity of ALD in a mice model [57].

FGF-21 exerts profound effects on energy expenditure and whole-body glucose metabolism largely in the adipose tissue via an insulin-independent manner. Adipose tissue production of adiponectin is increased in FGF21 transgenic mice and markedly inhibited in FGF21-null mice, possibly because of the impaired 'autocrine loop' between FGF21 and PPARy [58]. Similarly, serum adropin level is higher in mice fed with HFD than mice with chow diet. Adropin knock-out mice exhibit a 50%-increase in increase in adiposity while injection of bioactive peptide adropin effectively improves insulin resistance and metabolic flexibility in HFD-fed mice [59].
mice [17, 18]. Fetuin-A mRNA expression is elevated in NASH compared with steatosis patients [59]. Interestingly, accumulated fetuin A protein (but no mRNA can be detected) is observed in subcutaneous adipose tissue of obese than that of non-obese human, implying that fetuin A potentially acts as a hepatokine taken up by adipose tissue directly from the liver or circulation rather than local production [60]. Angiopoietin-like protein-3 and -4 (ANGPTL3/4) are circulating hepatokines acting on lipoprotein lipase (LPL) inhibition to regulate plasma lipid levels [61]. ANGPTL8/betatrophin, or lipasin, is expressed primarily in liver and visceral adipose tissue and can promote hepatosteatosis and plasma triglyceride levels in humans. Its action on LPL activation needs the co-inhibition of ANGPTL3/4 to enhance triglyceride uptake [62]. Retinol-binding protein 4 (RBP4) is primarily secreted from the liver but also released from adipose tissue as an adipokine. Serum and hepatic RBP4 levels are associated with NAFLD to NASH progression in clinical trials [63, 64]. Adipocyte-derived RBP4 further contributes to insulin resistance and obesity [65]. Hepatocyte-specific knockdown of rbp4 (without influence in white adipose tissue) improved insulin sensitivity and glucose metabolism in diabetic mice [66]. Recent study found that increased serum concentrations of ANGPTL1, 2, 8, and FGF21, as well as decreased levels of ANGPTL4 and adiponectin were associated with NAFLD-associated HCC [67].

Liver-pancreas communication

Liver and pancreas play complementary roles in glucose metabolism and homeostasis. Interlobular and total pancreatic fat are both positively related to NAFLD activity score and total pancreatic fat is a significant predictor for the presence of NAFLD in patients [68]. Another study also indicates that fatty liver plays a prognostic role in acute pancreatitis [69]. Excessive alcohol ingestion often leads to evident pancreatic injury. Both a single occasion of binge drinking and chronic alcohol consumption can increase the risk of an acute attack of pancreatitis. In the US, approximately 1 in 3 cases of acute pancreatitis and 4 in 10 causes of chronic pancreatitis are caused by alcohol, respectively [70, 71]. Metabolites of alcohol (e.g. acetaldehyde) processed by the pancreas damage the acinar cells, promote premature intracellular digestive enzyme activation, and thereby induce the local autodigestive injury [72]. Importantly, acute pancreatitis patients with liver cirrhosis have higher inpatient mortality compared to non-cirrhotics, possibly due to complications of cirrhosis and portal hypertension itself during the decompensated stage [73].

In 2013, Yi et al., claimed that ANGPTL8 secreted from the liver controlled pancreatic beta cell proliferation and mass increase [74]. However, this observation was quickly challenged and proved to be incorrect by following studies which found that Angptl8 knockout mice exhibited no abnormalities in terms of glucose homeostasis and/or in beta cell expansion in response to HFD- or insulin receptor antagonist S961-induced insulin resistance [75], and liver-specific overexpression of Angptl8 did not increase beta cell proliferation in mice [76]. Fetuin-A induces chemokine (MCP-1 and IL-8) and cytokine (IL-6) production in human pancreatic pre-adipocytes and adipocytes. It also stimulates IL-1β expression in islet-infiltrating macrophages through TLR4, which reveals the role of fetuin-A-mediated metabolic crosstalk between fatty pancreas and fatty liver [77]. Hepatocyte-derived kisspeptin1, under the control of glucagon, will transport to pancreas and binds to abundantly expressed kisspeptin 1 receptor in the beta cells, to inhibit cyclic AMP production and insulin secretion [78]. It has been demonstrated that pancreatic FGF21 was a digestive enzyme secretagogue whose physiologic function was to maintain acinar cell proteostasis [79], and restoring pancreatic FGF21 reverses pancreatitis induced by cerulein, alcohol, or endoscopic retrograde cholangiopancreatography [80]. However, whether liver-secreted FGF21 participate such process remains largely unknown. Moreover, damaged pancreas may secrete pro-inflammatory cytokines (e.g. TNF-α) to directly attack the liver per se.

Liver-eye communication

Modern clinical investigations suggest that noticing common manifestations in the eyes can help people prevent or address an issue with liver well-being, such as scleral icterus reflecting jaundice and xanthelasma palpebra for possible hepatic steatosis. Supplementation with lutein, a well-recognized eye health-promoting carotenoid, improved oxidative stress and inflammation in the liver and eyes of guinea pigs fed a hypercholesterolemic diet [81]. A recent study even found that retinitis pigmentosa-induced oxidative stress in the retina might influence soluble macromolecules exiting the retina or significantly impair the melanopsin system, resulting in chronic circadian desynchronization and weakened systemic antioxidant defense, which ultimately caused hepatic oxidative stress [82]. Another interesting study found that bright-light therapy towards the eyes could clinically ameliorate pruritus of cholestasis since this chronic liver disease-related skin disorder was centrally mediated by endogenous opioid peptides...
that induce disrupted circadian rhythm [83]. In a mice HE model, we identified that thioacetamide-challenged liver could release proinflammatory cytokines (TNF-α and IL-6) to cause impairments in the brain and eyes. Amelioration of liver injury significantly improved eyesight and cognition in mice [84]. This is in line with a previous clinical report in which a patient with severe acute liver failure had uncontrolled intracranial hypertension and needed a hepatectomy that resulted in stabilization of the systemic and cerebral hemodynamics. The removal of the liver was associated with a sharp and sustained reduction in the circulating proinflammatory cytokine concentration [85]. A recent study revealed that FGF-21 administration suppressed retinal neovessel concentration [86]. What and how liver-derived hepatokines and cytokines are delivered to the eyes are the most urgent questions to be answered.

Liver-bone communication

The prevalence of osteopenia/osteoporosis/fractures in chronic liver disease is between 12% and 55%, which is much higher in cholestatic diseases [87]. Hepatic osteodystrophy commonly manifests with osteoporosis and osteopenia, while osteomalacia is rare [88]. The pathogenic mechanisms for hepatic osteodystrophy are not well defined and are considered to be multifactorial. Impaired IGF-1 secretion from the liver might be one of the causative factors of hepatic osteodystrophy because it is a bone collagen and osteoblast stimulator [89]. In addition, increased unconjugated bilirubin can inhibit osteoblast differentiation and proliferation [90]. The association between viral hepatitis and bone dysfunction has been established in recent years. For example, untreated hepatitis C virus (HCV) infection is found to have a higher fracture risk [91]. Interestingly, except in the African-American population, untreated hepatitis B viral (HBV) infection had no significant difference in the incidence of hip fracture when compared with uninfected controls [92]. Low body weight, malnutrition, smoking habits, alcohol consumption, opioids or antidepressive drug use, and hypogonadism will also contribute to viral hepatitis-associated bone disease [93]. Similarly, several recent cross-sectional and case-control studies have shown that NAFLD patients have a greater prevalence of decreased BMD than age-, sex-, and body mass index-matched healthy controls [94, 95]. Proven links between NAFLD and decreased bone mass include vitamin D insufficiency [96], the growth hormone/IGF-I axis [97], TNF-α [98], the receptor activator of NF-κB (RANK)/osteoprotegerin pathway [99], fetuin-A [100], osteopontin [101], and adiponectin [102]. In addition, chronic inflammation and irisin from osteoblasts have been proposed as mediators of mutual interactions among the skeleton, fatty tissue, and liver [103]. Patients with ALD often have accompanying decreased vitamin D levels, which is primarily attributed to reduced hepatic 25-hydroxylase activity, malabsorption, irregular feeding habits and lack of sun exposure [104]. Zinc deficiency is also described among chronic alcoholics. Since zinc stimulates osteoblastic bone formation and mineralization, its deficiency decreases bone mass and is associated with an increased risk of fracture [105]. Blockade of liver-derived IGFBP-1 inhibits bone loss mediated by FGF-21 without inhibiting insulin sensitivity. In vivo administration of IGFBP-1 promotes osteoclast differentiation and bone resorption [106].

Liver-heart communication

Manifestations from the liver are very common in cardiac dysfunction or congestive hepatopathy. The pathological features of chronic cardiogenic liver disease include liver congestion, sinusoidal dilatation, necrosis and fibrosis in the central lobule of the liver [107]. Patients with acute heart failure and/or hypovolemia often develop hypoxic hepatitis, which has similar clinical manifestations as acute viral hepatitis. In addition, cirrhosis can further lead to the redistribution of circulating blood volume, as well as abnormal cardiac contractility and electrophysiology, which in turn leads to cirrhotic cardiomyopathy [108]. Half of the patients with cirrhosis had prolonged QT (Q wave to T wave) intervals, which might be an important factor to evaluate patient survival and prognosis. In addition, the plasma membrane fluidity, calcium channel disorders, and many factors such as cytokines, nitric oxide and endocannabinoids, also participate in the pathophysiological processes of cirrhotic cardiomyopathy [109].

Several systematic conditions affect the liver and heart simultaneously. NAFLD and cardiovascular diseases are usually related to metabolic disorders, such as obesity and diabetes. A multicenter community-based longitudinal cohort study has shown that NAFLD is an independent risk factor for subclinical myocardial remodeling and dysfunction after the assessment of body mass index (BMI) and ventricular activation time (VAT). Patients with NAFLD demonstrated cardiac diastolic dysfunction and had higher left ventricular (LV) mass, LV end-diastolic volume, and LV relative wall thickness than non-NAFLD participants [110]. A NAFLD risk allele TM6SF2 (transmembrane 6 superfamily member 2; rs58542926 c.449 C>T, p.Glu167Lys) was
found to be associated with dyslipidemia and cardiovascular risk, primarily due to impaired lipolipidation and reduced secretion of VLDL (very-low-density lipoprotein) particles from the liver [111]. The heart and liver are also common targets of alcohol abuse, which has been proved to damage the heart structure to a greater extent than to the liver [112]. The liver-heart inflammatory axis has a pivotal pathological role in the development of hepatic cardiomyopathy. Cannabinoid-2 receptor activation markedly improved hepatic/myocardial inflammation, decreased serum TNF-α level, and cardiac dysfunction, underlining the importance of inflammatory mediators in the pathology of this disease [113]. Hepatocyte-specific knockout of IL-6 was sufficient to block aging-induced cardiac arrhythmia in a fruit fly model [114]. In addition to the characterized linking function of adiponectin [19] and fetuin [33], a recent study reported that alpha-1-microglobulin (AMBP) exacerbated inflammation and disturbed hepatic fibrotic repair after myocardial infarction through activating Akt, NF-κB, and ERK signaling and promoting macrophage migration and polarization [115]. Another hepatokine, hepcidin, has been proven to regulate macrophage inflammation and arterial stiffness, thus promoting the development of atherosclerosis [116, 117]. Upregulated fetuin B aggravates myocardial ischemia/reperfusion injury through inhibiting insulin signaling in diabetic mice [118]. Gut microbial metabolism of choline results in hepatic production of trimethylamine-N-oxide (TMAO), which exacerbates atherosclerosis via promoting forward cholesterol transport [119, 120]. In an acute myocardial infarction mice model, it was revealed that supplementation of IL-22 markedly prevented left ventricular dysfunction and heart failure via liver-derived STAT3-FGF21 production, in which hepatocyte-specific knockout of STAT3 or FGF21 blocked such alleviation of IL-22 [121].

Liver-kidney communication

Hepatorenal syndrome is a serious complication that can lead to death. It is caused by severe liver diseases (e.g., acute liver failure and cirrhosis) and induce progressive kidney failure [122]. Apart from that, a number of liver disorders may also involve renal damage, such as viral hepatitis, ALD, NAFLD, and Wilson disease [123]. Two major renal diseases associated with chronic HBV are membranoproliferative glomerulonephritis and polyarteritis nodosa. Membranoproliferative glomerulopathy, IgA nephropathy, and amyloidosis may also occur [124]. In a recent retrospective cohort analysis involving 56,448 HCV patients in the United States, these patients had a 27% increased risk of chronic kidney diseases (e.g., membranoproliferative glomerulonephritis, and cryoglobulinemia) compared with patients without HCV in which the viral protein deposits may mediate the interorgan pathogenesis [125]. Patients with ALD have a tendency to exhibit impaired sodium and fluid handling, as well as severe alterations in the body’s acid-base balance, which directly influence the homeostasis of the kidneys [126]. Intuitively, alcoholics should have a higher risk of chronic kidney disease. However, one meta-analysis comprising 20 studies with a total of 292,431 patients found a decreased risk or no risk of kidney disease in heavy alcohol consumers [127]. This result was confirmed by other similar studies showing that the incidence of kidney disease is comparable or even lower in heavier drinkers (>210 g/wk of ethanol) than in moderate drinkers (70-210 g/wk of ethanol) [128, 129]. Emerging evidence suggests that NAFLD aggravates insulin resistance and atherogenic dyslipidemia, promoting the release of proinflammatory, prooxidant, profibrogenic, and procoagulant mediators from the liver or kidneys to induce renal injury [130]. Interestingly, although vitamin D deficiency has been linked to the pathogenesis and severity of NAFLD and renal diseases, benefits of vitamin D supplementation remain controversial, which may require higher dose treatment or vitamin D receptor agonists (e.g., paricalcitol) to be overcome [131]. Although the detailed mechanism remains controversial, the application of a recombinant hepatokine protein, AMBP, has been proven to be effective for ischemic acute kidney injury and chronic renal disorder therapies [132]. In an angiotensin II-induced vascular dysfunction mouse model, replenishment of FGF-21 directly regulates the multi-organ crosstalk between liver, adipose tissue, kidney, and blood vessels to improve hypertension and renal injury [12]. As a key regulator of the entry of iron into the circulation, hepcidin is also believed to contribute to increased iron sequestration and subsequent anemia in patients with chronic kidney disease [133]. A very recent study found that IL-6-mediated hepatocyte production was the primary source of plasma and urine neutrophil gelatinase-associated lipocalin during acute kidney injury [134].

Liver-skin communication

The notion of ‘skin reflects liver health’ have been recognized for a long time. For example, jaundice is usually recognizable when serum bilirubin levels are high. Whether the excessive bilirubin is conjugated or unconjugated implies whether the cause is prehepatic, intrahepatic, or posthepatic [135].
When the neutralizing function of the liver is disrupted, deposition of toxins and filtered bile salts in the skin causes irritation and itching [136]. Another well-known skin sign of severe liver disorder is spider angiomas induced by elevated estrogen levels, such as in cirrhosis [137]. Recently, interorgan communication between the liver and the skin under pathological conditions has received much attention. Acyl-CoA-binding protein (ACBP) knockout mice display delayed metabolic adaptation to weaning. Further mechanistic studies found that this phenomenon, including hepatic lipid adaptation, was caused by ACBP deficiency in the skin rather than in the liver [138]. The association between liver disease and psoriasis has been reported by several studies. For example, studies suggested that psoriasis may be more severe in patients with NAFLD/NASH [139, 140]. Mice fed a high-fat diet developed steatohepatitis reminiscent of human NASH. Cotreatment with imiquimod, a commonly used agent for psoriasis-like systemic inflammation models, exacerbated psoriatic phenotypes, including scale formation and acanthosis, through an IL-17A-dependent mechanism [141]. Conversely, another study found that a 9-week topical treatment with imiquimod induced typical psoriasiform dermatitis and, surprisingly, moderate portal/peripoortal hepatitis and liver fibrosis in mice. Livers from psoriatic mice were enriched for macrophages, polymorphonuclear neutrophils, and T cells [142]. AIH is often concomitant with extrahepatic autoimmune diseases. The positive association between AIH (particularly type 2 AIH) and vitiligo is well documented. Probable associations are also identified with alopecia areata, psoriasis, and pyoderma gangrenosum, although they were probably underdiagnosed and underreported in patients with AIH [143]. IGF-1 released from the liver contributes to skin wound healing. Deficiency of IGF-1 receptor keratinocytes disrupts epidermal homeostasis and stem cell maintenance [144]. Of note, all of the organs from liver specific IL-22 transgenic mice had a normal histology except for slightly thicker epidermis and minor inflammation in the skin compared with WT mouse skin [145]. However, the exact communicating mechanisms are not well characterized.

**Liver-spleen communication**

Liver cirrhosis often leads to splenomegaly and frequently accompanying hypersplenism, which is considered the main cause of cytopenia and thrombocytopenia in those patients [146]. Portal vein blockade is widely considered the initial cause of splenomegaly during liver cirrhosis. Conversely, since the spleen is the body’s largest immune organ and plays an important role in the production of antigen-specific T cells and numerous cytokines, a recent study demonstrated the effects of splenic immunity on liver fibrosis and reported that after liver injury, T helper (Th)1 cells suppressed liver fibrosis, while Th2-dominant splenic lymphocytes migrated into the liver and promoted liver fibrosis by shifting the cytokine balance towards Th2 dominance [147]. Splenectomy also accelerates hepatic regeneration in cirrhotic animals and patients with cirrhosis and inhibits the formation of hepatic fibrosis [148, 149]. Potential activation of splenic macrophages and subsequent transforming growth factor (TGF)-β1 production might be the major mechanisms. After splenectomy, the capacity of liver regeneration is improved by the decrease in TGF-β1 and the increase in hepatocyte growth factor. Splenectomy significantly increased the hepatic accumulation of Ly-6C(lo) monocytes or macrophages in a thioacetamide-induced murine model of liver cirrhosis with hypersplenism, implicating a role for the splenic control of hepatic monocyte or macrophage phenotypes [150]. Moreover, splenectomy suppressed regulatory T cell and hepatic fibrogenesis levels, implicating a role for the splenic modulation of the liver via alterations in T cell subsets [151]. Splenectomy improved liver function in patients with liver cirrhosis, especially with large spleen and lower alanine aminotransferase (ALT) levels, and stem cell therapy efficacy [152].

Several reports have discussed the messengers linking the liver and the spleen. An early interesting study found that the modification of inflammatory mediator generation by splenectomy or inhibition of Kupffer cell function may be beneficial for the prevention of endotoxin-induced liver injury after partial hepatectomy [153]. Another study demonstrated that cytokine expression in the spleen affects the progression of liver cirrhosis through liver-spleen crosstalk. Expression of TGF-β1 and cytokines such as IL-6 produced by macrophages could affect the progression of liver fibrosis and regeneration in patients with liver cirrhosis [154]. Foxp3-expressing CD25+CD4+ Treg cells in the spleen lead to tolerance of immunity after liver transplantation [155]. Enlargement of spleen is commonly seen in patients with of NAFLD, which is caused by disrupted iron metabolism, low vitamin D status, and increased cytokine communication (e.g. IL-6). Moreover, inflamed the visceral adipose tissue during NAFLD may also induce splenic injury via adipokines and cytokines [156].
Liver-lung communication

From a physiological point of view, the lung and the liver are closely coordinated. When liver function is perturbed, the inactivation of enterogenous pulmonary vasodilators by hepatocytes is lost, contributing to the accumulation of vasodilators [157]. At the same time, the increase in nonenteric vasodilators leads to the abnormal expansion of pulmonary vascular and gas exchange disorders, which further triggers hypoxemia and a series of other pathophysiological changes and clinical symptoms. These symptoms are clinically known as hepatopulmonary syndrome, which is common in patients with cirrhosis [158]. Tuberculosis (TB) is a chronic respiratory infection caused by *Mycobacterium tuberculosis*, which invades multiple organs and systems, with lung infections being the most common. Hepatic manifestation is seen in up to 50-80% of TB cases. Coinfection with HCV greatly promotes the occurrence of liver damage in patients with pulmonary tuberculosis, possibly because of decreased erythrocytes and T lymphocytes [159]. It should be noted that anti-TB drugs, including the three major first-line drugs isoniazid, rifampicin, and pyrazinamide, are the most common adverse events necessitating therapy interruption and causes of DILI, which has a general incidence of 5.3% [160]. Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is an inflammatory response regulated by multiple inflammatory mediators and cytokines. Activation of the liver X receptor alpha (LXRα) pathway has been shown to alleviate LPS-induced ALI by the natural product platycodin D [161]. Decreased fetuin A predicts increased disease activity in obstructive lung disease, Crohn’s disease, and ulcerative colitis [162]. Serum fetuin A promotes Lewis lung carcinoma in a calcium-dependent fashion [163]. By using omics methods, it was identified that circulating fetuin B and andropin levels could be used as biomarkers for lung function evaluation in COPD (chronic obstructive pulmonary disease) and myeloperoxidase anti-neutrophil cytoplasm autoantibody-associated lung injury patients, respectively [164, 165]. Other communicating proteins are yet to be discovered for the liver-lung communication.

Conclusions

Keeping a stable internal environment requires precise regulation of whole-body homeostasis in which organ-organ communication plays critical roles (Figure 2 and Table 2). Since the liver is responsible for a variety of physiological processes, disruptions of homeostatic balance warrant a rapid and well-regulated response from it, in most cases, via paracrine and endocrine signaling molecules, to rebalance itself and distant organs. Importantly, new study has revealed that NAFLD had higher overall risk of incident cancers than obesity without NAFLD, possibly because hepatic ectopic fat act as a paracrine source for cancer development in the liver, gastrointestinal tract and uterus [166]. The past decade has witnessed the discovery of a set of hepatokines in many physiological and pathological conditions, in particular, metabolic liver diseases [167]. Indeed, other common and rare liver diseases also require communication from the liver to other organs to alleviate pathological events such as inflammation and cell death and to promote local tissue regeneration. Although the functions of several hepatokines and cytokines in organ-organ communications have been preliminarily analyzed, most studies only described the phenotypic relationships between the liver and other organs under different conditions, with the mystery of the direct communicating mediators unanswered. Hence, a future challenge will be to focus on the signals and to elucidate the modulatory mechanisms of liver-generated molecules in disease progression and communication. Specifically, (1) although substantial progress has been made in understanding disease-controlled production of hepatokines, little is known about the inductive mechanism of transcriptional reprogramming, protein translation, modification, and secretion of hepatokines, particularly through the ER and Golgi, by pathological processes; (2) feedback signaling from distant organs that are induced by hepatokines and the reciprocation between hepatokines and other ‘organokines’ are poorly recognized. Several proteins (e.g. FGF21 and soluble epidermal growth factor receptor) can be secreted from the liver and other organs, which act as hepatokine, adipokine, and/or myokine under different circumstances [168, 169]. How these signals are spatio-temporally regulated to maintain functional interorgan communication is largely unknown, which needs cutting-edge techniques, such as specific cell type-transgenic method and single-cell sequencing, to answer; (3) whether different liver diseases (e.g., viral hepatitis and metabolic liver diseases) share similar hepatokine secretion profiles needs further investigation. That is, from a translational perspective, searching a single or set of hepatokines as biomarkers for certain diseases is critical for clinical applications. For metabolic liver diseases, one of the central problems is that they rarely induce specific symptoms and diagnosis is frequently incidental. Recent studies using multomics approach identified that hepatokine tsukushi was a potential blood biomarker and drug treatment target of NAFLD and subsequent
atherosclerosis [170, 171]. Indeed, such findings need to be confirmed in large cohorts of corresponding patients (e.g. the pilot clinical findings of FGF21 and LECT2 in diabetic patients) [172, 173]; (4) Through the use of advanced mass spectrometry "omics" approaches, we now recognized that liver functions as an endocrine organ by secreting a wide array of hormones (e.g. IGF-1) and noncoding RNAs (miR-9 and -375 for pancreatic insulin regulation), in addition to hepatokines and cytokines, that exert powerful effects on metabolic processes both in the liver and in peripheral tissues [174]. Future studies that interrogate the hepatocyte or liver secretomes using multomics approaches are well positioned to identify novel communicating ‘messengers’. Addressing these challenges will be of major interest for the understanding of liver-centered organ-organ communication, as well as the development of rational therapeutic strategies for certain diseases.

Figure 2. Distant communicating mechanisms, including neuronal, hormonal, metabolic, and other factors, between major organs under pathological conditions. 5-HT, 5-hydroxytryptamine; AIH, auto-immune hepatitis; ANGPTL, angiopeitn-like protein; DILI, drug-induced liver injury; FFA, free fatty acids; GI, gastrointestinal; IgA, immunoglobulin A; I/R injury, ischemia/reperfusion injury; PBA, primary bile acids; RAS, renin-angiotensin system (Created with BioRender.com).

Table 2. Involvement of the liver in other organ’s disorders

| Organ          | Disorder                                      | Hepatic manifestation                                      | Possible linking mechanisms                                                                 | Refs                      |
|----------------|----------------------------------------------|------------------------------------------------------------|---------------------------------------------------------------------------------------------|--------------------------|
| Brain          | Cognitive disorder (e.g. Alzheimer’s disease) | Cholestatic liver disease and fatty liver disease           | Bile acids                                                                                  | [39]                     |
|                | Hepatic encephalopathy                       | Cirrhosis and liver failure                                 | Ammonia, cytokines, and hepatokines                                                        | [42, 43, 176, 177]       |
|                | Circadian behavior disorder                  | Lipid dysregulation                                         | FGF-21                                                                                      | [50, 51]                 |
| Adipose tissue | Ecotopic expansion and adipocyte death       | NAFLD and ALD                                               | FGF-21, ANGPTLs, adropin, fetuin-A                                                         | [17, 57-59, 67]          |
| Pancreas       | Acute and chronic pancreatitis               | NAFLD and ALD                                               | ANGPTLs, fetuin-A, kispeptin                                                                | [75, 77, 78]             |
| Eyes           | Retinal injury                               | NAFLD and ALD                                               | Oxidative stress and cytokines                                                              | [81, 178]                |
|                | Retinitis pigmentosa                         | Liver injury                                                | Oxidative stress                                                                            | [82]                     |
| Bone           | Hepatic osteodystrophy                       | PBC and PSC                                                | IGF-1, bilirubin,                                                                          | [88, 90]                 |
|                | Fracture                                     | Viral hepatitis, NAFLD, and ALD                             | Hepatokines, hormones, and vitamins                                                        | [91, 92, 95, 96, 98, 100, 101, 106] |
| Heart          | Heart failure and cardiomyopathy            | Liver fibrosis/cirrhosis                                    | Cytokines, calcium, NO, and endocannabinoids                                               | [107-109]                |
|                | Diastolic dysfunction                        | NAFLD                                                      | Free fatty acids (?)                                                                        | [110]                    |
|                | Myocardial infarction                        | Hepatic inflammation and disorders                           | Hepatokines                                                                                 | [115-117]                |
| Kidneys        | Hepatorenal syndrome                        | severe liver diseases (e.g. alcoholic cirrhosis,           | Cytokines and hepatokines                                                                    | [122]                    |
Scholar (2019B151502013).

5. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of liver disease. Theranostics. 2019; 71: 2029-212.

References

6. Meeks RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017; 13: 509-20.

7. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018; 98: 2133-223.

8. Degirolamo C, Sabha C, Moschetta A. Therapeutic potential of the endocrine functions of the liver: report of the 1st International Workshop on Therapeutic Endocrine Liver Diseases. Nat Rev Drug Discov. 2016; 15: 51-69.

9. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009; 58: 250-9.

10. Keipert S, Lutter D, Schroeder BO, Brandt D, Stahlman M, Schwarzmayr T, et al. Endogenous FGF21-signalizing controls paradoxical obesity resistance of UC-P21-deficient mice. Nat Commun. 2020; 11: 624.

11. Ye D, Wang Y, Li H, Jia W, Man K, Lo CM, et al. Fibroblast growth factor 21 protects against acacetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated antioxidant capacity in mice. Hepatology. 2014; 60: 977-89.

12. Pan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J, et al. FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotension-(1-7) Axis in Mice. Cell Metab. 2018; 27: 3133-37.e5.

13. Morovat A, Weerasinghe G, Neshit V, Hofer M, Agnew T, Quaghebeur G, et al. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. J Clin Med. 2017; 6.

14. Gao S, Milimian RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in the peptide hormone adiponectin. Diabetes. 2014; 63: 3242-52.

15. Aydin S. Three new players in energy regulation: pretinin, adiponectin and irisin. Peptides. 2014; 56: 94-110.

16. Gao S, Ghoshal S, Zhang L, Stevens JR, Commins KS, Finck BN, et al. The peptide hormone adiponectin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem. 2019; 294: 13366-77.

17. Gao S, Milimian RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Adiponectin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012; 20: 1394-402.

18. Thapa D, Stoner MW, Zhang M, Xie B, Manning JR, Guimaraes D, et al. Adiponectin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-FDG4 signaling pathway. Redox Biol. 2018; 18: 25-32.

19. Kwon OS, Andtbacka RHI, Hyngstrom JR, Richardson RS. Vasodilatory secretion (e.g. NO) of adropin and adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012; 20: 1394-402.

20. Thapa D, Stoner MW, Zhang M, Xie B, Manning JR, Guimaraes D, et al. Adiponectin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-FDG4 signaling pathway. Redox Biol. 2018; 18: 25-32.

21. Kwon OS, Andtbacka RHI, Hyngstrom JR, Richardson RS. Vasodilatory function in human skeletal muscle feed arteries with advancing age: the role of adiponectin. J Physiol. 2019; 597: 1791-804.

22. Sugiyama F, Haroak S, Watanabe T, Shiota N, Taniguchi K, Ueno Y, et al. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab Invest. 1997; 76: 835-42.

23. Yamannoiris, F. Wang, Y. Shoomaker R, Laroan T, Thompson J, English VL, et al. Deficiency of angiotensinogen in hepatocytes markedly decreases blood pressure in lean and obese male mice. Hypertension. 2015; 66: 836-42.

24. Matsuoka T, Niimura F, Shizuma A, Pastan I, Saito A, Kobori H, et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol. 2012; 23: 1381-9.

25. Yamannoiris F, Karounos M, Charrigo R, English VL, Ratner DL, Daugherty A, et al. Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol. 2012; 302: R244-51.

26. Yamannoiris F, Gupre M, Putnam K, Thatcher S, Charrigo R, Rateri DL, et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension. 2012; 60: 1524-30.

27. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Gousti A, et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahog gene. Diabetes. 2002; 51: 2450-8.

28. Rittig K, Thamer C, Haupt A, Machann J, Peter A, Ballesteros D, et al. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis. 2009; 207: 341-2.
28. Ish JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, et al. Feto-A and incident diabetes mellitus in older persons. Jama. 2008; 300: 182-9.
29. Takata H, Ieda Y, Sueno T, Ishibashi A, Inoue M, Kumon Y, et al. High glucose induces transactivation of the alpha2-HS glycoprotein gene through the ERK1/2-signaling pathway. J Atheroscler Thromb. 2009; 16: 448-56.
30. Pal D, Dasgupta S, Kundu R, Maitra D, Das G, Mukhopadhyay S, et al. Feto-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012; 18: 1279-85.
31. Dasgupta S, Bhattacharya S, Biswas A, Majumdar SS, Mukhopadhyay S, Ray S, et al. NF-kappaB mediates lipid-induced feto-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J. 2010; 429: 451-62.
32. Chattopadhyay M, Mukherjee S, Chatterjee SK, Chattopadhyay D, Das S, Majumdar SS, et al. Impairment of energy sensors, SIRT1 and AMPK in lipid induced inflamed adipocyte is regulated by feto-A. Cell Signal. 2012; 24: 67-76.
33. Mees RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, et al. Feto-A is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose current review. Hepatol Int. 2018; 12: 1078-89.
34. Wang PY, Caspi L, Lam CK, Chari M, Li X, Light PE, et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature. 2008; 452: 1021-6.
35. McMillin M, Fampston G, Quinn M, Ashfaq S, de los Santos M, 3rd, Grant S, et al. Bile Acid Signaling Is Involved in the Neurological Defects in a Model of Acute Liver Failure. Am J Pathol. 2016; 186: 312-23.
36. Yanguas-Casas N, Barreda-Manso MA, Nieto-Sampedro M, Romero-Ramirez T, LUDCA: An Agonist of the Bile Acid Receptor GPR109A With Anti-Inflammatory Effects in Microglial Cells. J Cell Physiol. 2017; 232: 2231-41.
37. Mertens KL, Kalsbeck A, Soeters MR, EggiH JM. Bile Acid Signaling Pathways from the Enterohormone Circulation to the Central Nervous System. Front Neurosci. 2017; 11: 1-16.
38. Ackerman HD, Gerhard GS. Bile Acids in Neurodegenerative Disorders. Front Aging Neurosci. 2016; 8: 263.
39. MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease—An emerging role for gut microbiome. Alzheimers Dement. 2019; 15: 76-92.
40. Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, et al. Intestine-derived farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolic function. Hepatology. 2018; 68: 1574-88.
41. Hadjihambi A, Arias N, Sheikz M, Jalan R. Hepatic encephalopathy: a critical current review. Hepatol Int. 2018; 12: 135-47.
42. Apte MV, Pirola RC, Wilson JS. Mechanisms of alcoholic pancreatitis. J Gastroenterol Hepatol. 2010; 25: 109-100.
43. Cheung GW, Kokorovic A, Lam CK, Chari M, Lam HK. Intestinal microbial challenge in the hepatic encephalopathy. Expert Rev Gastroenterol Hepatol. 2010; 4: 539-42.
44. Manakatt V, Vijay GK, Hu C, Peng J, Garcia-Martinez I, Hoque R, et al. A bile acid agonist improves cognitive dysfunction in a murine model of Alzheimer’s disease. Cell Mol Gastroenterol Hepatol. 2019; 8: 325-36.
45. Kim JE, Clark RM, Park Y, Lee J, Fernandez ML. Lutein decreases oxidative stress and inflammation in liver and eyes of guinea pigs fed a hypercholesterolemic diet. Nutr Res Pract. 2012; 6: 113-9.
46. Peridis L, Fuentes-Broto L, Segura F, Ben Gdara N, Sanchez-Cano AI, Insa G, et al. Bile acid oxidative stress in pigmented P2Y12 thrombosis transgenic rats with progressive retinal degeneration. Free Radic Biol Med. 2018; 124: 550-7.
47. Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol. 2001; 96: 2532-6.
48. Cox AR, Lam CJ, Bonnyman CW, Chavez J, Rios JS, Kushner JA. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Cell Metab. 2017; 25: 223-31.
49. Wang PY, Caspi L, Lam CK, Chari M, Li X, Light PE, et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature. 2008; 452: 1021-6.
50. Wang X, Chen X, Zhang H, Pang J, Lin J, Xu Y, et al. Circulating retinoid-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease. Diabetes Metab. 2020; 46: 119-28.
51. Pettis S, Tripodo C, Giraudon C, Cabili D, Cammà C, Di Cristina A, et al. High farnesoid X receptor protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Dig Liver Dis. 2011; 43: 404-10.
52. Kim JE, Clark RM, Park Y, Lee J, Fernandez ML. Lutein decreases oxidative stress and inflammation in liver and eyes of guinea pigs fed a hypercholesterolemic diet. Nutr Res Pract. 2012; 6: 113-9.
53. Coate KC, Hernandez G, Thorne CA, Sun S, Le TDV, Vale K, et al. FGF21 Is an Angiopoietin-like Protein in Angiogenesis, Inflammation and Cancer. Int J Radiat Oncol Biol Phys. 2015; 92: 1656-63.
54. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, et al. Bile Acid Signaling Is Involved in the Neurological Defects in a Model of Acute Liver Failure. Am J Pathol. 2016; 186: 312-23.
55. Marcelin G, Silveira ALM, Martins LB, Ferreira AV, Clement K. Deciphering the cellular interplay underlying obesity-induced adipose tissue fibrosis. J Clin Invest. 2019; 129: 4032-40.
56. Ghaben AL, Scherer PE. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol. 2020; 21: 242-58.
57. Luo P, Zheng M, Zhang R, Zhang H, Liu Y, Li W, et al. S-alliin-mercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling. Acta Pharmacol Sin. 2020; 21: 1-10.
58. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013; 17: 779-89.
59. Kahnamin A, Sowa JP, Schlattmann M, Sydr S, Pronadl M, Wree A, et al. Feto-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond). 2013; 125: 391-400.
60. Khadir A, Kavalakatt S, Madhu D, Hammad M, Devarajan S, Tuomilehto J, et al. Feto-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation. Lipids Health Dis. 2018; 17: 29.
encephalopathy pathogenesis and Lycium barbarum polysaccharides protection. J Ethnopharmacol. 2020; 248: 112357.

85. Jalan R, Pollock A, Shah SH, Madhavan K, Simpson KJ. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol. 2002; 37: 536-8.

86. Fu Z, Gong Y, Lieg R, Wang Z, Liu CH, Meng SS, et al. FG21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice. Cell Rep. 2017; 18: 1606-13.

87. Wang X, Shen L, Ye P, Cao R, Yang X, Xiao W, et al. The association between Hepcidin and arterial stiffness in a community-dwelling population. Lipids Health Dis. 2018; 17: 244.

88. Malhotra R, Wunderer E, Barnes JH, Bagchi A, Buswell MD, O'Rourke CD, et al. Hepcidin Deficiency Protects Against Atherosclerosis. Arterioscler Thromb Vasc Biol. 2019; 39: 178-87.

89. Xing W, Tan Y, Li K, Tian P, Tian F, Zhang H. Upregulated hepatokine fetuin B aggravates myocardial ischemia/reperfusion injury through inhibiting insulin signaling in diabetic mice. J Mol Cell Cardiol. 2020.

90. Wang Z, Klipfel E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2019; 57: 56-73.

91. Tresed M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015; 277: 717-26.

92. Tang TT, Li YY, Li JJ, Wang K, Han Y, Dong WY, et al. Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction. Theranostics. 2018; 8: 4552-62.

93. Gines P, Sola E, Angeli P, Wong F, Nadim KM, Kamath PS. Hepatorenal syndrome. Nat Rev Nephrol. 2013; 9: 4-8.

94. Noble J, Jouve T, Malvezzi R, Pestaing L. Renal complications of liver diseases. Expert Rev Gastroenterol Hepatol. 2018; 12: 1135-42.

95. Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018; 38: 23-32.

96. Park H, Chen C, Wang W, Henry L, Cook RL, Nelson DR. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018; 67: 492-504.

97. Varga ZV, Matyas C, Paloczi J, Pacher P. Alcohol Misuse and Kidney Injury: Epidemiological Evidence and Potential Mechanisms. Alcohol Res. 2017; 38: 263-8.

98. Cheungpasitporn W, Thongprayoon C, Kattanmongkolchai W, Bracve BC, O VG, Amin OA, Edmond JH, et al. High alcohol consumption and the risk of renal damage: a systematic review and meta-analysis. Qjm. 2015; 108: 539-48.

99. Sato KK, Hayashi T, Uehara S, Kinuhata S, Oue K, Endo G, et al. Drinking pattern and risk of chronic kidney disease: the kansai healthcare study. Am J Nephrol. 2014; 40: 516-22.

100. Koning SH, Gansvoort RT, Mulkam KJ, Rimm EB, Bakker SJ, Joosten MM. Alcohol consumption is inversely associated with the risk of developing chronic kidney disease. Kidney Int. 2015; 87: 1009-16.

101. Tangher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017; 13: 297-310.

102. Musso G, Cassader M, Cohnhey S, De Michieli F, Pinach S, Saba F, et al. Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. J Am Soc Nephrol. 2016; 27: 3830-45.

103. Zager RA. Alpha1-Microglobulin: A Potentially Paradoxical Antioxidant. Adv Exp Med Biol. 2017; 9.

104. Sheeetz M, Barrington P, Callies S, Berg PH, McCombol J, Marbur T, et al. Targeting the hepatokine-fetuin-A pathway in anemia of chronic disease. Br J Clin Pharmacol. 2019; 85: 935-48.

105. Skrypnyk NI, Gig K, Okamura K, Montford JR, You Z, Yang H, et al. IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrobil gelatinase-associated lipocalin during acute kidney injury. Kidney Int. 2020; 97: 966-79.

106. Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician. 2004; 69: 299-304.

107. Majeo M, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007; 45: 666-74.

108. Doga S, Jindal R. Cutaneous manifestations of common liver diseases. J Clin Exp Hepatol. 2011; 1: 177-84.

109. Neess D, Klok Bo W, Bekksgaard M, Marcher AB, Faerger MJ, Mandrup S. Delayed hepatic adaptation to weaning in ACBP-/- mice is caused by dysfunction of the epithelial barrier. Cell Rep. 2013; 5: 1403-12.

110. Miele L, Vellone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Hepcidin Deficiency Protects Against Atherosclerosis. Arterioscler Thromb Vasc Biol. 2019; 39: 178-87.

111. Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012; 53: 190-7.

112. Vasseur P, Morni J, Joug EJF, Pohin M, Delawal A, Petit-Pars I, et al. High-Fat Diet-Induced IL-17A Exacerbates Psoriasis Dermatitis in a Mouse Model of Steatohepatitis. Am J Pathol. 2016; 182: 2293-2302.

113. Vasseur P, Morni J, Joug EJF, Favit L, Venisse N, McLehy J, et al. Liver fibrosis is associated with upregulated inflammation in rats with the several early and mild morphological features of psoriasis dermatitis. Br J Dermatol. 2018; 179: 101-9.
